Two more Big Pharma CEOs enjoyed hefty raises in 2018, leaving the industry’s only major league female chief in firm control of last place

By any measure, Merck had a big year in 2018 as its PD-1 drug cruised into first place for the megablockbuster checkpoint market. And CEO Ken Frazier, who started the year by earning headlines for directly rebuking President Donald Trump, was rewarded with a fat, 19% hike in compensation.